rosiglitazone has been researched along with Cardiac Remodeling, Ventricular in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguila, MB; Mandarim-de-Lacerda, CA; Torres, Tda S | 1 |
| Bu, PL; Hao, MX; Hou, XY; Li, CB; Liu, JN; Ti, Y; Wang, ZH; Zhang, W; Zhang, Y; Zhao, XQ | 1 |
| de Roos, A; Dehnavi, RA; Lamb, HJ; Mertens, BJ; Roes, SD; Tamsma, JT; Westenberg, JJ | 1 |
| Aimaretti, G; Cittadini, A; Isgaard, J; Longobardi, S; Monti, MG; Napoli, R; Netti, PA; Rea, D; Saccà, L; Samà, M; Walser, M | 1 |
| Green, DE; Hart, CM; Kang, BY; Kleinhenz, JM; Murphy, TC; Page, P; Sutliff, RL; Szyndralewiez, C | 1 |
| Amin, R; Kariharan, T; Nanayakkara, G; Quindry, J; Viswaprakash, N; Zhong, J | 1 |
| Clarke, K; Cole, MA; Hulbert, K; Lygate, CA; Monfared, M; Neubauer, S | 1 |
| Amiri, F; Diep, QN; Iglarz, M; Paradis, P; Schiffrin, EL; Touyz, RM; Viel, EC | 1 |
| Geng, DF; Jin, DM; Wang, JF; Wu, W; Wu, YM | 1 |
1 trial(s) available for rosiglitazone and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome.
Topics: Aged; Combined Modality Therapy; Diet; Double-Blind Method; Exercise; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Linear Models; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; Netherlands; Predictive Value of Tests; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; Ventricular Remodeling | 2011 |
8 other study(ies) available for rosiglitazone and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Rosiglitazone reverses cardiac adverse remodeling (fibrosis and vascularization) in perinatal low protein rat offspring.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Diet, Protein-Restricted; Fibrosis; Heart; Hypoglycemic Agents; Male; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Ventricular Remodeling | 2010 |
Rosiglitazone attenuates myocardial remodeling in spontaneously hypertensive rats.
Topics: Animals; Collagen Type I; Collagen Type III; Hypertension; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; NF-kappa B; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factor AP-1; Treatment Outcome; Ultrasonography; Up-Regulation; Ventricular Remodeling | 2011 |
Metformin prevents the development of chronic heart failure in the SHHF rat model.
Topics: Animals; Blood Glucose; Blood Pressure; Chronic Disease; Gene Expression Regulation; Heart Failure; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Ventricular Remodeling | 2012 |
The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation.
Topics: Animals; Cell Hypoxia; Cell Proliferation; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Gene Expression; Gene Knockdown Techniques; Humans; Hydrogen Peroxide; Hypertension, Pulmonary; Lung; Mice; Mice, Inbred C57BL; Myocytes, Smooth Muscle; NADPH Oxidase 4; NADPH Oxidases; PPAR gamma; Proliferating Cell Nuclear Antigen; Pulmonary Artery; Pyrazoles; Pyrazolones; Pyridines; Pyridones; RNA Interference; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta1; Ventricular Remodeling | 2012 |
PPARγ activation improves the molecular and functional components of I(to) remodeling by angiotensin II.
Topics: Angiotensin II; Animals; Atrial Remodeling; Cardiotonic Agents; Cells, Cultured; Diabetic Cardiomyopathies; Down-Regulation; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Myocytes, Cardiac; Oxidative Stress; Potassium Channels, Voltage-Gated; PPAR gamma; Protein Transport; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Rosiglitazone; Thiazolidinediones; Ventricular Remodeling | 2013 |
The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cardiotonic Agents; Drug Therapy, Combination; Echocardiography; Heart Failure; Male; Myocardial Infarction; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Treatment Failure; Ventricular Remodeling | 2003 |
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Desoxycorticosterone; Endothelin-1; Endothelins; Fenofibrate; Fibrosis; Heart; Heart Ventricles; Hypertension; Myocardium; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Ventricular Remodeling | 2003 |
Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction.
Topics: Angiotensin II; Animals; Blood Glucose; Body Weight; Collagen; Insulin; Ligands; Liver; Lung; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Organ Size; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Ventricular Remodeling | 2006 |